Released Mar 17, 2023, after the close
10-Q filed Mar 17, 2023, 45 days after period end · 0001654954-23-003131
Q1 2023 · 10-Q
Revenue$4.24M$4.24M −15.6% vs Q1 2022−8.6% vs Q4 2022
Net Income$426.43K$426.43K +39.7% vs Q1 2022+146.0% vs Q4 2022
EPS, diluted—
Gross Profit$1,240,156−0.4%
Operating Income$328,632−7.6%
Operating Cash Flow$875,866N/M
Free Cash Flowderived$867,799N/M
Margins · derived
Gross margin29.3%+4.5 pt vs Q1 2022
Operating margin7.8%+0.7 pt vs Q1 2022
Net margin10.1%+4.0 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $4.24M | $5.02M | $4.49M | $4.61M |
| Net Income | $426.43K | $305.24K | $268.03K | $526.90K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR